New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
作者： Bruno Vincenzi , Daniele Santini , Giuseppe Tonini
关键词:
摘要:
jco.org参考文章(4)
Daniel J. Hicklin, Lee M. Ellis, Harlan W. Waksal, Andrea T. Hooper, Marie C. Prewett, Rajiv Bassi, Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts Clinical Cancer Research. ,vol. 8, pp. 994- 1003 ,(2002)
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025
Ki Young Chung, Jinru Shia, Nancy E. Kemeny, Manish Shah, Gary K. Schwartz, Archie Tse, Audrey Hamilton, Dorothy Pan, Deborah Schrag, Lawrence Schwartz, David S. Klimstra, Daniel Fridman, David P. Kelsen, Leonard B. Saltz, Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry Journal of Clinical Oncology. ,vol. 23, pp. 1803- 1810 ,(2005) , 10.1200/JCO.2005.08.037
José Baselga, Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy Oncologist. ,vol. 7, pp. 2- 8 ,(2002) , 10.1634/THEONCOLOGIST.7-SUPPL_4-2